Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Jan 15 2019 Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
- Dec 20 2018 Galectin Therapeutics Announces Extension of $10 Million Line Credit
- Nov 19 2018 Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
- Nov 13 2018 Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update